BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22419576)

  • 1. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.
    Yoshida A; Zokumasu K; Wano Y; Yamauchi T; Imamura S; Takagi K; Kishi S; Urasaki Y; Tohyama K; Ueda T
    Haematologica; 2012 Sep; 97(9):1372-9. PubMed ID: 22419576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis?
    Heredia FF; de Sousa JC; Carvalho AF; Magalhaes SM; Pinheiro RF
    Haematologica; 2012 Oct; 97(10):e37-9; author reply e40. PubMed ID: 23053671
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome.
    Badran A; Yoshida A; Wano Y; Mutoh M; Imamura S; Yamashita T; Tsutani H; Inuzuka M; Ueda T
    Int J Oncol; 2003 Jan; 22(1):59-64. PubMed ID: 12469185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
    Ye D; Garcia-Manero G; Kantarjian HM; Xiao L; Vadhan-Raj S; Fernandez MH; Nguyen MH; Medeiros LJ; Bueso-Ramos CE
    J Hematop; 2009 Mar; 2(1):2-8. PubMed ID: 19669217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
    Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
    Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
    Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
    Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome that progressed to acute myelomonocytic leukemia with eosinophilia showing peculiar chromosomal abnormality: a case report.
    Kim SH; Suh C; Choi SJ; Kim JG; Lee JH; Kim SB; Kim SW; Lee KH; Lee JS; Kim WK; Kim SH; Seo EJ; Chi HS
    J Korean Med Sci; 1999 Aug; 14(4):448-50. PubMed ID: 10485627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related myeloid neoplasms following treatment with radioiodine.
    Schroeder T; Kuendgen A; Kayser S; Kröger N; Braulke F; Platzbecker U; Klärner V; Zohren F; Haase D; Stadler M; Schlenk R; Czibere AG; Bruns I; Fenk R; Gattermann N; Haas R; Kobbe G; Germing U
    Haematologica; 2012 Feb; 97(2):206-12. PubMed ID: 21993688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myelodysplastic syndromes. Part I. What are they? Part II. Classification.
    Galton DA
    Scand J Haematol Suppl; 1986; 45():11-20. PubMed ID: 3515515
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia.
    Kirimura S; Kurata M; Nakagawa Y; Onishi I; Abe-Suzuki S; Abe S; Yamamoto K; Kitagawa M
    Pathology; 2016 Apr; 48(3):233-41. PubMed ID: 27020498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: natural history and features of prognostic importance.
    Mufti GJ; Galton DA
    Clin Haematol; 1986 Nov; 15(4):953-71. PubMed ID: 3552350
    [No Abstract]   [Full Text] [Related]  

  • 13. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes.
    Schildgen V; Wulfert M; Gattermann N
    Exp Hematol; 2011 Jun; 39(6):666-675.e1. PubMed ID: 21447369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
    Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
    Cleven AH; Nardi V; Ok CY; Goswami M; Dal Cin P; Zheng Z; Iafrate AJ; Abdul Hamid MA; Wang SA; Hasserjian RP
    Mod Pathol; 2015 Apr; 28(4):552-63. PubMed ID: 25412846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome.
    Borges DP; Dos Santos AWA; Paier CRK; Ribeiro HL; Costa MB; Farias IR; de Oliveira RTG; França IGDF; Cavalcante GM; Magalhães SMM; Pinheiro RF
    Leuk Res; 2018 Jan; 64():61-70. PubMed ID: 29220700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
    Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
    Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
    Suciu S; Kuse R; Weh HJ; Hossfeld DK
    Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.